Moderate to Severe Dry Eye
Pipeline by Development Stage
Ophthalmology is a $3.7B market with a mature, consolidating portfolio dominated by glaucoma treatments and emerging corneal/retinal therapies.
Key Trends
- Glaucoma therapeutics (prostaglandin analogs, adrenergic agents) represent 60%+ of spending but face patent cliffs 2028-2034
- Innovative mechanisms (NGF agonists, LFA-1 antagonists, RTKIs) gaining traction in dry eye and retinal disease segments
- Heavy trial activity (2,656 total) skewed toward Phase 4 (369) and Phase 3 (442), indicating mature clinical development landscape
Career Verdict
Ophthalmology offers stable mid-career opportunities with strong Commercial and Medical Affairs salaries, but limited innovation catalysts and significant patent cliff risk warrant careful timing of entry.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | LUMIGAN (Bimatoprost) | AbbVie | $697M | 19% | LOE_APPROACHING | Declining | |
| 2 | OXERVATE (Cenegermin-BKBJ) | Unspecified | $493M | 13% | PEAK | Stable | |
| 3 | XIIDRA (Lifitegrast) | Bausch + Lomb | $473M | 13% | PEAK | Stable | 7.6yr |
| 4 | INLYTA (Axitinib) | Pfizer | $467M | 13% | PEAK | Growing | 11.2yr |
| 5 | HUMIRA (Adalimumab) | AbbVie | $258M | 7% | LOE_APPROACHING | Declining |
Drug Class Breakdown
mature, losing exclusivity
peak growth in corneal disease
sustained peak sales
expanding in retinal indications
mature, multiple LOE approaching
mature, losing exclusivity
mature immunology approach
Career Outlook
StableOphthalmology offers predictable mid-career growth with strong Commercial ($158K) and Medical Affairs ($247K) compensation but faces structural headwinds: patent cliffs 2028-2034 eliminate $97M in revenue, glaucoma franchise maturity limits blockbuster potential, and modest trial volume (2,656) signals incremental R&D expansion. Best suited for professionals seeking stable roles in established therapeutic areas rather than disruptive innovation.
Breaking In
Enter via Clinical Operations or Commercial analyst roles at CROs (Syneos 210 jobs) or large diagnostics players (Labcorp 904) to build domain expertise before targeting pharma MSL/Medical Affairs positions.
For Experienced Professionals
Experienced professionals should prioritize Medical Affairs and Market Access roles leveraging mature market knowledge; avoid product-specific expertise in glaucoma due to patent cliff concentration, and consider adjacent areas (retinal, corneal) where innovation catalysts remain.
In-Demand Skills
Best For
Hiring Landscape
Ophthalmology hiring (3,202 jobs) is distributed across diagnostics/devices (Labcorp 904, Abbott 348) and pharma commercial functions rather than concentrated in R&D. Top pharmaceutical employers (Pfizer 60, AstraZeneca 100, Regeneron 168) show modest pharma-specific headcount relative to market size, suggesting outsourced CRO and distributor dependency. Medical Affairs ($247K avg salary) commands premium compensation, signaling high barrier to entry but strong mid-career upside.
Top Hiring Companies
By Department
Clinical Operations and Commercial roles offer entry-level stability ($150K-$158K); Medical Affairs commands premium salaries ($247K) but requires advanced credentials; limited R&D hiring (207 jobs) suggests constrained innovation investment.
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 38 trials with date data
Clinical Trials (38)
Total enrollment: 3,237 patients across 38 trials
Optimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery
Artificial Tears, Tear Lipids and Tear Film Dynamics
Digital Device Users Who Are Treated With Systane Hydration PF
Direct Application of Systane Complete to Contact Lenses
Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort
A Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients
Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects
Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye
Evaluation of the Repeated Usage of Systane Ultra Eyedrop
A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes
A Study of the Efficacy and Safety of Cyclosporin Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease
Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes
Efficacy of a New Nanoemulsion Artificial Tear Targeting Dry Eye Disease
Systane® Ultra Preservative Free Lubricant Eye Drops
Systane® Hydration PF and Systane® Hydration Preserved
Systane® Complete Preservative Free Lubricant Eye Drops
Systane Hydration in Subjects Undergoing Cataract Surgery
Systane Complete Multi-symptom Relief
Evaluation of Comfort in Subjects With Moderate Dry Eye Disease
Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops
Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease
Clinical Outcomes Following Treatment With SYSTANE® BALANCE
Clinical Evaluation of Systane® Balance in Dry Eye Subjects
Evaluation of Clinical Outcomes After the Use of SYSTANE® HYDRATION
Clinical Evaluation of Systane® Gel Drops in Dry Eye Subjects
Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects
The Effect of SYSTANE® BALANCE on Tear Film Break Up Time in Dry Eye Subjects
Systane Ultra Versus Maxidex Versus Saline
Comparative Efficacy of SYSTANE® ULTRA vs Optive™ in Improving Tear Film Break-up Time
Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline
Barrier Function Measurement in Dry Eye Patients After Using Systane Ultra for 30 Days
Evaluate the Ability of Systane Ultra to Improve Subjective Symptoms of Ocular Irritation Post 60 Min. Athletic Performance.
Residence Time Evaluation of Marketed OTC Ophthalmic Products
A 2-week Clinical Comparison of SYSTANE® Ultra to Sensitive Eyes Rewetting Drops in Contact Lens Wearing Patients.
Acute Comfort and Blurring Profile Evaluation of Marketed Lubricant Eye Drops
Acute Comfort and Blur of Systane Ultra and Systane
Evaluation of SYSTANE Ultra Lubricant Eye Drops
The Effect of Systane Ultra Lubricant Eye Drops (FID 112903) on Visual Performance
Related Jobs in Ophthalmology
Technical Writer
IT Support Specialist
Ophthalmology Account Manager - Midlands
Ophthalmology Account Manager - East of England
Lab Assistant I
Sr. Mechanical Engineer
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.